Case Study: Actionable, Qualified Spatial Profiling of Pharmacodynamic-Relevant Tumor–Immune Biology in NSCLC
The next evolution of spatial biology is the transition from exploratory imaging toward controlled generation of quantitative spatial metrics associated with pharmacodynamic-relevant tumor biology.
In non-small cell lung cancer (NSCLC) immuno-oncology studies, the challenge is not simply identifying immune cells within the tissue, but understanding whether their spatial organization reflects biologically meaningful mechanisms associated with therapeutic activity, immune exclusion, suppression, or cytotoxic engagement.
This case study illustrates how a qualified multiplex spatial panel can be deployed on FFPE NSCLC tissue to generate reproducible and biologically interpretable spatial metrics associated with pharmacodynamic (PD)-relevant tumor–immune biology. The objective: implementation of a controlled multiplex framework capable of moving beyond descriptive multiplex imaging toward more quantitative spatial characterization of immune biology.
Download the case study below.
Ready-to-Use Standalone Biomarkers
Understanding tissue biology at high resolution requires both flexibility and reliability. At Aliri, we provide a curated portfolio of verified standalone protein markers compatible with immunofluorescence and imaging mass cytometry (IMC) workflows.
These markers are designed to seamlessly complement our ready-to-use panels or to be deployed as individual targets, enabling tailored experimental designs without compromising on quality or timelines.
Download the full list of standalone biomarkers below.
Ready-to-Use Biomarker Panels: Oncology Collection
From tumor initiation to therapeutic response, oncology research increasingly depends on biomarker data that must be robust, translatable, and clinically meaningful. Clinicians and translational teams now require the simultaneous assessment of an expanding number of biomarkers to better capture tumor heterogeneity, mechanisms of resistance, and patient response to therapy.
To expedite your research and minimize development costs, we have translated our years of oncology biomarker expertise into 24 ready-to-use panels. These panels are designed to address key oncology questions that are critical for understanding disease biology and therapeutic response, including for example:
- Tumor characterization
- Immune contexture
- Pathway activation
- Target engagement
- Patient Stratification
Download the brochure to view a full list of panels and biomarkers in our Oncology Collection.
Ready-to-Use Biomarker Panels: Immunology & Inflammation Collection
From disease onset to therapeutic response, Immunology and Inflammation research increasingly relies on biomarker data that must be robust, translatable, and biologically meaningful. Clinicians and translational teams now require the simultaneous assessment of growing numbers of biomarkers to better capture disease complexity, patient heterogeneity, and treatment response.
To expedite your research and minimize development costs, we have translated our years of immunology and inflammatory biomarker expertise into 23 ready-to-use panels. These panels are designed to address key disease-relevant questions about disease onset, progression, and response to therapy, including for example:
- Immune cell activation and differentiation
- Cytokine and chemokine signaling
- Tissue inflammation
- Pathway dysregulation
- Patient stratification
Download the brochure to view a full list of panels and biomarkers in our Immunology & Inflammation Collection.
